Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
REAL-WORLD EFFECTIVENESS OF RSV VACCINES AMONG ADULTS USING TARGET TRIAL EMULATION IN EPIC COSMOS
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10001
- Pfizer
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will include non-pregnant adults aged ≥18 years and ≥ 60 years in the United States with care observed in Epic Cosmos, contributing healthcare systems on or after August 2023. Individuals will be required to have sufficient healthcare engagement to ensure adequate data capture and observability within the database. Within this population, vaccinated individuals will be identified by documented administration of an RSV vaccine in structured EHR data.
Description
Inclusion:
Vaccinated Cohort
Patients must meet all the following inclusion criteria to be eligible for inclusion in the study:
- Adults meet the age criteria at the index date.
- Non-pregnant at the index date.
- Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
- Have a documented administration of ABRYSVO® (or AREXVY®,mRESVIA® in the later phase) in Epic Cosmos on or after August 2023.
The index date for vaccinated individuals will be defined as the date of RSV vaccination.
Unvaccinated Cohort
Patients must meet all the following inclusion criteria to be eligible for inclusion in the study (in unvaccinated cohort):
- Adults meet the age criteria at the index date.
- Non-pregnant at the index date.
- Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
- Have no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date.
The index date for unvaccinated individuals will be defined as the start date of each sequential trial ('e.g.', 1st date of each month) in which they met eligibility criteria
Exclusion:
Exclusion Criteria Vaccinated Cohort
Patients meeting any of the following criteria will not be included in the study:
- Individual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses).
- Non-US residents. Unvaccinated Cohort
Patients meeting any of the following criteria will not be included in the study (in unvaccinated cohort):
- Individual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above.
- Non-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Vaccinated group
Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna) |
|
Unvaccinated comparator group:
Individuals not yet vaccinated at cohort entry, but otherwise eligible |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization
Time Frame: up to 3 years
|
up to 3 years
|
|
Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization
Time Frame: up to 3 years
|
up to 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of RSV-related outcomes
Time Frame: up to 3 years
|
ARI/LRTD non-inpatient encounter, ARI/LRTD severe outcome, ARI/LRTD critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, Immunocompromised status and pneumonia with different care settings. |
up to 3 years
|
|
Incidence of All-cause outcomes
Time Frame: up to 3 years
|
all-cause ARI/LRTD encounter with different care settings, severe outcome, critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, pneumonia with different care settings, Immunocompromised status and dementia (new onset). |
up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- C3671094
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.